CTIX News 08/25/2014 18:28:05 $CTIX TOB this is a good

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
CTIX News 08/25/2014 18:28:05 $CTIX
TOB this is a good board and I noticed you were absent during much of the malaise of the past year. Good to see you back engaged. CTIX has real potential and may make many here a lot of money!
Hey Miles, read the linked article. Interesting. They got some right. Mostly wrong in the interpretations, IMO. I think you agree. Time will certainly tell.

The trader part in me could care less. One nice thing when trading. I listen to the market, not my inner voice.

Course, the investor in me did the research and put a long term position on. Haven't changed my very, positive fundamental assessment of CTIX in over two years.

I briefly subscribed to Hot Stocks. Came to believe my own analysis was doing better than theirs. Other words: Trades based on their system underperformed my own trades (hard to explain what my system is).

Always my best to you.



CTIX Stock Message Board http://investorshangout.com/Cellceutix-Corpor...TIX-87375/

You said it better than I. Thanks.

I like the addition of "semi-smart" money to the equation, to differentiate from Institutional. The "semi-smart" CTIX has already. If we have any "smart money" Institutional, its likely at the nibble level and at the small end of the definition.

I always enjoy and value your posts.
Great day today for CTIX! Looking for that close above $2.15 before a retrace and test of Support at $2.05 or$2.10 which ever one the market wants to take us to test. Then a nice chart cool down and reset launching us past our all time high before settling in to a whole new price regime based on real time news!

Congrats Patience Longs!
Here's an article by a man not looking very deeply...

http://www.hotstocked.com/article/87917/cellc...gains.html

Thanks for the notice, guy. Now sulk away and prepare your apology.
Think or Swim/TD Ameritrade also shows today's CTIX volume as 698,454, the same as iHub

Interesting that those others show the same, lower number. Must be a common price feed issue, but I don't know the details. No doubt an OTC issue.

The other's numbers still puts today as above average volume, and higher than yesterday, so a similar chart read IMO. But with that said, more is better.




TOB...Yahoo, Etrade, Nasdaq, freerealtime all show 619,309 shares traded. The only place I see 698,000 is on I-hub. It's hard to figure out how 80,000 shares got added to I-hub or didn't get counted on all the other services. I suppose at some point it will need to be sorted out for the historical record. Will it make a difference in the charts, one versus the other?

Interesting post. I try and let you (and a few others) do the heavy lifting for me on potential valuations for CTIX. My mind turns to mush when I start contemplating all the potential inputs and thru puts and end points. Mush.

About K: Can't get around K being unrewarded partially because it has been so successful in trials. Keeps proving to be very safe, no end to cohorts in sight. But, I know what all this really adds up to in the end, MORE $$$$.

While B and P likely will find faster routes to market, I still believe the most valuable gem to be K.

Can't forget about the autism compound and other goodies in the vault either.

BigK, thanks again for a very enlightening post.


I think so BK. You add so much to this board, its time for the rocket!!!
I like the volume of the past few weeks. Around 4M total shares traded. This is enough to allow someone (or multiple someone's) to build a decent position. I'm still not sure we have any real institutional buying at this point. The total value of the rally is less than 10M in trade value. (if we were seeing 25-50M in value then I think bigger players are engaging)

I still think this rally is still primarily semi-smart and retail money. Semi-smart are individuals who are professionals with decent portfolios and have a few hundred thousand to play with. They have a higher risk tolerance and play in the margins (looking for high beta stocks) which CTIX may become. However, real "smart money" is going to wait for a drug to be proven to work or if they get wind of a deal or trial outcome. They'll want to deploy 10s of millions into the trade. It's too much work to follow a bunch of small investments.

If the volume and rally continue to build and increase, I'd start to lean towards someone (or a group) taking a decent position (or information is leaking and friends and family are buying in mass).

I'm still planning to add another 100k shares on good news. If Brilacidin works we're on our way to a home run. On it's strength alone $10-20/share is very doable. If we get positive news on Kevetrin and Brilacidin, it could get very exciting.

It should be a fun fall
While TOB has his "Rally [Chimp]," it's time for me to break out my "Rocket to the Moon!" siggie.

Why CTIX?

#1 Brilacidin:

Since the Polymedix acquisition last year, the adding of their assets, and in particular Brilacidin, was not met by an expected increase in valuation. Instead, following the acquisition a long slide from 2.20 region to 1.40 ensued. This in spite of a $200 valuation of the Brilacidin asset prior to Phase 2b trial start. Even as the end of the trial is now official, and the announcement that B-ABSSSI performed at least as expected, the share price is only just now approaching the price just prior to the acquisition a year ago.

Add to the B-ABSSSI Phase 2b announcement that of a pending INDA for Brilacidin-OM, followed by Brilacidin-Ocular, Brilacidin-Otic, and Brilacidin-Diabetic Foot Infections/Ulcers and the Brilacidin value becomes something well north of $200 million. So, discounting and further increased valuation following the Phase 2b trial, the market still does not as of yet recognize any value in the rest of the platform. This will change.

#2 Kevetrin (many would put this at #1)

Kevetrin has long been the flagship drug for CTIX, though arguably recently replaced by Brilacidin. Kevetrin is the platform drug. Following successful Phase 1 studies, there are already 2 more studies planned at world class research centers, MD Anderson and University of Bologna, with a third trial planned at Beth Isreal, all at no, or almost no, cost to CTIX and its shareholders.

Drawbacks to Kevetrin are that it is in the most expensive development arena of biopharma, ontology, and the current trial could go on for at least another 6 months, possibly even a year. Then, there is some question whether or not it will be effective as a stand alone drug, which means to some that developing each combination therapy will mean each requiring a Phase 1b start. CTIX will need funding for these trials, which means partnering, even if a license with $50 million up front is reached for any drug in its pipeline.

On the other hand, as noted above, there is much available in support for a new, effective addition to anticancer therapies, and the efficacy that K targets is considered to be the holy grail of oncology, at least for 50% of all cancers. The high cost and high potential is the balance reflected in the shareprice and cap over the past 18 months, until last week. Nonetheless, the SP is still inside the extended flag reaching all the way back to January 2013.

The question for shareholders, current and future, looking back Brilacidin and the lack of added valuation since its acquisition, to what extent is the current cap reflective of total added values as Brilacidin and its many forms and Kevetrin as an emerging platform? I would postulate that we are currently not more than half way there at $2, and probably a third of the way.

#3 Prurisol

This drug was to be the "meal ticket" for Kevetrin clinical trials until Brilacidin knocked it off its perch. In nonclinical testing, Prurisol was a functional cure of psoriasis. Not just lesion clearance as measured by PASI, but total, full disappearance for the nonclinical trial life of the subject mice. Nonetheless, since Prurisol shifted from proof of concept to FDA trial, several new and effective drugs have won FDA approval. The question remains, with increased competition, will Prurisol prove to be as effective in clinical trials as it has been in nonclinicals? Currently, we would not expect it to add value to the bottom line as the other two drugs now dominate that aspect of CTIX. Still, should Prurisol prove to be what it was in preclinical development, expect a billion dollars in increased cap following such a successful 2/3a trial, a trial that should be short and sweet at about 1 year's duration.

Putting it all together

Should the results of the Brilacidin-ABSSSI trial turn out as many expect--high efficacy, low toxicity, short duration regimen--expect a breakthrough therapy designation with a straight to NDA and clinical approval. In the meantime, clinical trials against other infections as well as formulations are already ramping up. A partnership or license deal should also be in the works and in place in Q1 2015.

Here is the caveat to the partnership and timing, 30 kg of Brilacidin in its current formulation is a lot of product even at the higher dose of 1.8 mg/kg over 3 days. Given Leo's explanation, for future clinical trials, that would be enough product for 250K patients, or 250 trials of 1000 patients each. 250 trials? Really? He expects >200 Phase 2/3 trials over the next year? Sufficient material for 150K patients, enough to treat 25% of all hospitalized ABSSSI for the entire first year, would also have enough left over for another 100 trials of 1000 patients each. Still a lot of trials. Do keep in mind that the other forms of Brilacidin are reformulations, so Leo can't be including those in his future trials.

As for Kevetrin, while a successful Cohort 8 and approval of 9 should be viewed buy the market as a great success, 215 mg/m2 deemed safe, advancement of trials, all trials, are still a year away. Still, each advancing cohort should also add value. And, should Brilacidin result in a partner, those future trials will be fully funded and that will change the valuation metric substantially for the better.

Prurisol will be Prurisol, and once that is clinically proven, it should result in an additional $10 a share over and above any valuation for B and K, if only for its billion dollar market potential.

IMO-FWIW
Interesting to note that CTIX rallied to $2.47 at the end of 2012 with the Kevetrin only at the start of its Phase 1 Clinical Trial at Harvard Cancer Centers.

That was long before Brilacidin made its surprise arrival, with Brilacidin now approaching Phase 2b Clinical Trial results in Q4

That was before the marvelous Aspire financing which allowed CTIX to advance with only minimal dilution. Unusual for an early stage bio-tech.

Now here we are in 2014, at the cusp of a flurry of Clinical Trials for three drugs, Kevetrin, Prurisol and Brilacidin, with Kevetrin now at a very advanced stage and dosage well into the expected therapeutic range with a proven safety profile.

Much justification for a higher CTIX share price, considering Cellceutix is vastly stronger now than it was at the end of 2012.
TOB, we will have to agree to disagree on this point.

But, I'm sure we can agree to agree that things are looking pretty good for CTIX, presently.


INH, Thx for your answer. I agree exciting times ahead for all of us longs. I have been a shareholder since 2011. It feels like it is all coming together now!!!!
Seems so, my friend.

noretreat, your post:

Quote:
a lot of things seem to be coming together nicely right now...


I am especially happy for investors like you, who have taken large and patient positions based on a good understanding of CTIX fundamentals. CTIX is way overdue for some positive recognition.

I think your faith in CTIX will be validated soon.


Excellent summary of events. The only thing I don't agree on is Polymedix management being respected. There were long brewing issues. Many considered the CEO as arrogant and that may have stalled potential partnerships.

For example, take a look at this post on the Polymedix board from Friday, 11/09/12 12:26:08 PM

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 166

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 114

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 81

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Accredited Debt Relief Earns Personalized Honor in 2026

Updated Category News Views 185

A High Score Is Useful, Not a Free Pass Debt relief rankings can get awfully shiny when a company has a good week, but this one has some actual detail behind it. USA Today named Accredited Debt Relief its best provider for personalized debt relief in its 2026 review, handing the company a 94 out of 100. The ranking was published November 11 and updated November 12, and...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 236

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 36

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 176

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 88

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading

Top 5 Most Recently Viewed Articles

Eagle Pharmaceuticals Board Advances Rights Plan for Shareholders

Updated Category News Views 231

Eagle Pharmaceuticals Board Extends Rights Plan Duration Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) has announced an update regarding its stockholder rights plan. The Board of Directors has approved an important amendment to the existing limited duration rights plan, extending its validity for one additional year, until October 30, 2026. Reason for the Amendment This...

Continue Reading
How Trump's Immigration Policies Could Impact US Growth

Updated Category News Views 338

Trump's Immigration Policies and Economic Growth Donald Trump's approach to immigration is likely to influence the rate of migration into the United States significantly, implying a potential slowdown in the nation's economic growth. Analysts at Piper Sandler have expressed concerns that the upcoming policies could lead to a meaningful deceleration in migration rates that...

Continue Reading
Sonder Holdings Faces Nasdaq Compliance Challenges Ahead

Updated Category News Views 142

Sonder Holdings Faces Nasdaq Compliance Challenges Sonder Holdings Inc. (NASDAQ: SOND), a cutting-edge hospitality company known for its tech-enhanced accommodations, recently received a formal notification from Nasdaq regarding a compliance issue. This is primarily due to the company's delay in filing its Q3 financial report for the period ending September 30, 2024. The...

Continue Reading
Join Us for the 2024 AvaSure Symposium Celebrating Virtual Care

Updated Category News Views 90

Overview of the 2024 AvaSure Symposium Healthcare professionals from across the country are preparing to convene for the 2024 AvaSure Symposium. This event will focus on the significant impact of AI-driven virtual care platforms on improving patient outcomes, enhancing staff satisfaction, and ensuring a healthy return on investment (ROI). Event Information The upcoming...

Continue Reading
Revolutionizing Scientific Communication: Stempad's Winter Update

Updated Category News Views 282

Revolutionizing Scientific Communication: Stempad's Winter Update Stempad, the world's first alternative for pen-and-paper scientific writing, has excited the academic community with the announcement of its new winter features. This innovative tool supports students, educators, and researchers in STEM fields, ensuring they have a seamless solution for effective scientific...

Continue Reading